Drugs / RADALBUVIR
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01431898 | Sep → Dec 2011 | chronic hepatitis C virus infection | Gilead Sciences | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT01984294 | Oct 2013 → Apr 2014 | chronic hepatitis C virus infection | Gilead Sciences | Completed | No outcome recorded |
| Phase 2 | NCT01826981 | Apr 2013 → Mar 2015 | chronic hepatitis C virus infection | Gilead Sciences | Completed | No outcome recorded |
| Phase 2 | NCT01805882 | Jan 2013 → Aug 2015 | chronic hepatitis C virus infection | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT01260350 | Dec 2010 → Oct 2013 | chronic hepatitis C virus infection | Gilead Sciences | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RADALBUVIR | ChEMBL registry synonym — accepted as the source's own label CHEMBL3121539 ↗ |
| Known as | GS-9669 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01826981 ↗ |
| Action | Inhibit | “NS5B non-nucleoside inhibitor GS-9669” PMID 24262278 ↗ Nov 2013 |
| Modality | Small molecule | “NS5B non-nucleoside inhibitor GS-9669” PMID 24262278 ↗ Nov 2013 |
| Route | Oral | “Oral treatment with Sofosbuvir 400mg (GS-7977), Ledipasvir 90mg (GS-5885), GS-9669 500mg, once daily for 6 weeks in HCV genotype 1, treatment naïve patients” NCT01805882 ↗ |